A New Polymorphism Biomarker rs629367 Associated with Increased Risk and Poor Survival of Gastric Cancer in Chinese by Up-Regulated miRNA-let-7a Expression

Qian Xu1, Qiguan Dong1, Caiyun He1, Wenjing Liu1, Liping Sun1, Jingwei Liu1, Chengzhong Xing1, Xiaohang Li2, Bengang Wang3, Yuan Yuan1*

1 Tumor Etiology and Screening Department of Cancer Institute and General Surgery, the First Affiliated Hospital of China Medical University, and Key Laboratory of Cancer Etiology and Prevention (China Medical University), Liaoning Provincial Education Department, Shenyang, Liaoning, China, 2 Gastrointestinal Surgery and Department 4 of General Surgery, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China, 3 Hepatobiliary Surgery and Department 1 of General Surgery, the First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China

Abstract

Background: Variant in pri-miRNA could affect miRNA expression and mature process or splicing efficiency, thus altering the hereditary susceptibility and prognosis of cancer. We aimed to assess miRNA-let-7 and single nucleotide polymorphisms (SNP) associated with the risk and prognosis of gastric cancer (GC) as predicting biomarkers, and furthermore, its possible mechanisms.

Methods: A two-stage case-control study was designed to screen four miRNA SNPs (pri-let-7a-2 rs629367 and rs1143770, pri-let-7a-1 rs10739971, pri-let-7f-2 rs17276588) in 107 GC patients, 107 atrophic gastritis (AG), and matched 124 controls using PCR-RFLP. Two promising SNPs were validated in another independent 1949 samples (including 579 gastric cancer patients, 649 atrophic gastritis and 721 controls) using Sequenom MassARRAY platform and sequencing.

Results: We found that pri-let-7a-2 rs629367 CC variant genotype was associated with increased risks of gastric cancer and atrophic gastritis by 1.83-fold and 1.86-fold, respectively. For gastric cancer prognosis, patients with rs629367 CC genotype had significantly poorer survival than patients with AA genotype (log-rank \(P=0.004\)). We further investigated the let-7a expression levels in serum and found that let-7a expression elevated gradually for rs629367 AA, CA, CC genotype in the atrophic gastritis group (\(P=0.043\)). Furthermore, we confirmed these findings in vitro study by overexpressing let-7a carrying pri-let-7a-2 wild-type A or polymorphic-type C allele (\(P<0.001\)).

Conclusions: pri-let-7a-2 rs629367 CC genotype could increase the risks of gastric cancer as well as atrophic gastritis and was also associated with poor survival of gastric cancer, which possibly by affecting the mature let-7a expression, and could serve as a predicting biomarker for high-risk and poor prognosis of gastric cancer.

Introduction

MicroRNAs (miRNAs) are 18–25 nucleotide (nt)-long, single-stranded noncoding RNA [1]. Any variation in pri-miRNA, pre-miRNA or mature miRNA may affect the mature process and function of miRNA, which could further affect the expression of hundreds of proteins in the interaction pathway [2]. To some extent, the variant of miRNA played a part as an “oncogene” or “tumor suppressor gene” indirectly [3].

let-7 is the second identified miRNA after the discovery of the first miRNA, lin-4 [4–6]. The let-7 family has 10 members including let-7a to let-7g, let-7i, miR-98 and miR-202. The let-7 family plays a crucial role in maintaining the normal physiologic function of human. For example, the pri-miRNA of let-7 family could combine with LIN28 and suppress the splicing procedure of Drosha and Dicer, two important restriction enzymes involving in the mature process for all miRNA [7]. In addition, by knocking down the Drosha enzyme to suppress all the miRNA mature process comprehensively, Kumar at al found that the main reason for the activation and promotion of cell’s malignant transformation was the downregulation of let-7 family expression [8]. Although many previous studies have contributed broadly to illustrate the biological functions of let-7 family, few study have focused on genetic variations of members of the family. In fact, if two individuals were selected randomly, their genomes may demonstrate about 0.1% diversity, of which the most common diversity was SNP [9]. Because of the existence of these diversities, the same gene can lead to different gene expression products.
which could result in different disease susceptibility, hereditary phenotype and prognosis of disease [10].

Previous studies demonstrated that the pri-miRNA SNPs may be used as genetic markers for predicting cancer risk. For example, pri-miR-185 rs2008591 was associated with risk of breast cancer [11]; pri-miR-34b/c rs4938723 was associated with risk of hepatocellular cancer [12]. In the present study, by using data of NCBI bioinformatics databases, we screened all SNPs in the primary precursor area of let-7 family (±600 bp), and found that only 4 SNPs (pri-let-7a-1 rs10739971, pri-let-7a-2 rs629367 and rs1143770, pri-let-7f-2 rs17276588) had Minor Allele Frequency (MAF) > 5% in Chinese population, and they were all tagSNPs in Hapmap database. So far, few studies have mentioned the relationship between the four tagSNPs and disease-risk prediction except for schizophrenic illness [13], non-small cell lung cancer [14] and diabetic nephropathy [15]. Their potential role in predicting cancer risk remains largely unknown.

Gastric cancer is the second leading cause of cancer death worldwide and one of the most frequent cancers in East Asian and Chinese populations [16–18]. Studies have showed that several miRNA SNPs were associated with gastric cancer risk [19–22]. However, whether the above-mentioned four tagSNPs in pri-miRNA genes of let-7 were associated with the risk of gastric cancer and atrophic gastritis in Chinese population, whether it can be used as a predictive genetic biomarker for gastric cancer, and the specific mechanism of how they regulate the disease risk still need to be clarified.

In this study, we first assessed the association between these four candidate tagSNPs in pri-let-7a and susceptibility of gastric cancer and its precursor by conducting a two-stage case-control study in Chinese. Meanwhile, we investigated whether the risk-associated polymorphism contributes toward gastric cancer patients’ survival. Furthermore, we examined the effect of the risk-associated polymorphism on regulating its mature miRNA expression in serum and gastric tissue as well as explored its possible regulatory mechanism in modulating disease risk and survival. By conducting the present study, we hope to propose the potential application prospect of the studied SNP as a prewarning biomarker for individuals with high-risk of gastric cancer and its precancerous disease (atrophic gastritis).

Methods

Patients and study design

This research project was approved by the Ethical Committee of the First Affiliated Hospital of the China Medical University and the study was divided into three independent but related parts including risk, prognosis and mechanisms research. The risk part was two stages designed, one is screening stage and the other is validated stage. To elucidate the association of candidate SNPs with gastric cancer and atrophic gastritis risks, the screening stage retrospectively recruited samples including 338 cases, consisting of 107 gastric cancer patients, 107 atrophic gastritis cases and 124 matched controls from the First Affiliated Hospital of China Medical University between 2003 and 2010. In the validated stage, we investigated a total of 1949 cases including 579 gastric cancer, 649 atrophic gastritis and 721 healthy controls from a health check program for gastric cancer screening in Zhuanghe of Liaoning Province, China or from the patients in the First Affiliated Hospital of China Medical University, between 2002 and 2013. All the subjects in this study were endoscopically and histologically confirmed. The classification of gastric cancer was divided into intestinal-type and diffuse-type for subgroup analysis which was based on Lauren’s classification [23,24]. The classification and grading of gastritis was based on the Updated Sydney System [25,26]. Subjects who were endoscopically and histologically confirmed with normal mucosa or only minimal gastritis without other systemic disease or other stomach diseases served as controls. Written informed consents were collected from the patients, and medical histories (including age, sex, smoking, and alcohol consumption) obtained by questionnaire and the records were computerized as previous described [24].

To further investigate the association of risk-associated polymorphism with clinicopathologic parameters and survival in gastric cancer patients, we used data of 130 gastric cancer cases, whose information of death or survival was available. The tumor histological grade was evaluated by World Health Organization criteria and tumors were staged using the 7th edition of the TNM staging system of the International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) (2010) based on postoperative pathologic examination. Patients (i) with distant metastasis found preoperatively, (ii) who underwent preoperative radiotherapy or chemotherapy, or (iii) with incomplete pathological data entries were excluded from the survival analysis. Follow up was completed by August 2013. Finally, 150 patients were included in the survival analysis.

For the evaluation of correlation between risk-associated polymorphism and its miRNA expression in serum, 364 cases including 164 gastric cancer, 100 atrophic gastritis and 100 healthy controls were examined. The characteristics of included subjects were shown in Supplementary Table S1. In addition, for the assessment of correlation between risk-associated polymorphism and its miRNA expression in gastric tissue, 97 non-cancerous specimens and 94 gastric cancerous specimens were obtained from 97 patients who underwent gastrectomy at the First Affiliated Hospital of China Medical University between 2009 and 2013.

Subject’s genotyping

Genomic DNA was extracted as described previously with some modifications [27]. The genotyping assay was performed by CapitalBio (Beijing, China) using the Sequenom MassARRAY platform (Sequenom, San Diego, CA, USA) as previously described [24]. 5% of the whole samples were repeatedly genotyped, and the concordance rate was 100%, demonstrating that the genotyping was correct. The detailed materials were shown in the Supplementary Methods.

The detection of serum H.pylori-IgG titer

According to the method described by the literature [28], serum H.pylori-IgG titer was detected by enzyme linked immunosorbent assay (ELISA, Helicobacter pylori IgG kit; Biohit, Helsinki, Finland). The detailed materials were shown in the Supplementary Methods.

RNA extraction and real-time PCR reaction for miRNA expression in vivo

The miRNA extracted method from the serum and tissue was used as described by the literature [29] with some modifications. The reverse transcription reaction was used One Step Prime Script miRNA cDNA (Perfect Real Time) Kit (TAKARA Biotechnology Co., Ltd, Dalian, China) and Real-time PCR reaction was used miRcute miRNA qPCR detection kit (SYBR) (Tiangen Biotech Co., Ltd, Beijing, China). The detailed materials were shown in the Supplementary Methods.
Transient transfection and real-time PCR reaction for miRNA expression in vitro

The commercial expression plasmid pCMV-MIR-let-7a-2 rs629367-C was purchased from Origene Company (Origene Biotech Co., Ltd, Shanghai, China). This plasmid was conducted a site-specific mutagenesis at -216 from C to A (pCMV-let-7a-2 rs629367-A) by Sainuo Company (Sainuo Biotech Co., Ltd, Beijing, China) and confirmed by sequencing. And the candidate cell lines were sequenced to genotype the pri-let-7a-2 rs629367 site to explore whether there was any variant of this rs629367 polymorphism site. Then, the cell lines of the wild-type and also the lowest two let-7a expression, SGC-7901 and AGS, were selected for transfection (More details see Supplementary Methods and Supplementary Figure S2). The human gastric carcinoma cell line, AGS was purchased from ATCC, American Type Culture Collection, USA and SGC-7901 was purchased from the Cell Bank of Chinese Academy of Sciences, Shanghai, China. After 72 hours, the total RNA of cells was extracted and Real-time PCR was used to detected let-7a expression after reverse transcription in order to compare the mature let-7a produced by pCMV-let-7a-2 rs629367-A vs. pCMV-let-7a-2 rs629367-C.

Table 1. The association of four studied pri-miRNA polymorphism and risks of gastric cancer/atrophic gastritis*.

| Polymorphism          | Screening Stage (Stage 1) | Validation Stage (Stage 2) |
|-----------------------|---------------------------|-----------------------------|
|                       | NCBI Ref(%)               | CON(%) | AG(%)  | AG vs CON | CON(%) | GC(%)  | GC vs CON | P       | OR(95%CI) | P       | OR(95%CI) |
| pri-let-7a-1 rs10739971 |                           |        |        |           |        |        |           |         |           |         |           |
| GG                    | 12(26.7)                  |        | 40(32.3) | 26(24.3) | 1   | 40(32.3) | 32(29.9) | 1   |         |         |           |
| GA                    | 26(58.0)                  |        | 67(54.0) | 52(48.6) | 0.593 | 1.190(0.63-2.23) | 67(54.0) | 59(55.1) | 0.819 | 1.070(0.59-1.93) |
| AA                    | 7(15.6)                   | 17(13.7) | 29(27.1) | 0.018 | 2.590(1.18-5.70) | 17(13.7) | 16(15.0) | 0.786 | 1.120(0.49-2.59) |
| AA VS. GA+GG          |                           |        |        |           | 0.015 | 2.340(1.18-4.61) | 0.817 | 1.060(0.51-2.24) |
| p<sub>in</sub>        | 0.254                     | 0.185 | 0.778 |           | 0.185 | 0.185 |           |         |           |         |           |
| pri-let-7a-2 rs629367  |                           |        |        |           |        |        |           |         |           |         |           |
| AA                    | 62(68.9)                  | 70(56.5) | 62(57.9) | 1   | 70(56.5) | 64(59.8) | 1   |         |         |           |
| CA                    | 26(28.9)                  | 46(37.1) | 39(36.4) | 0.942 | 0.980(0.56-1.71) | 46(37.1) | 41(38.3) | 0.948 | 0.980(0.57-1.69) |
| CC                    | 2(2.2)                    | 8(6.5)  | 6(5.6)  | 0.566 | 0.710(0.22-2.27) | 8(6.5)  | 2(1.9)  | 0.106 | 0.270(0.05-1.32) |
| CC VS. CA+AA          |                           |        |        |           | 0.574 | 0.730(0.24-2.23) | 0.819 | 1.060(0.51-2.24) |
| p<sub>in</sub>        | 1                         | 0.493 | 0.337 |           | 0.493 | 0.63  |           |         |           |         |           |
| pri-let-7a-2 rs1143770 |                           |        |        |           |        |        |           |         |           |         |           |
| CC                    | 17(40.5)                  | 21(16.9) | 26(24.3) | 1   | 21(16.9) | 21(16.9) | 1   |         |         |           |
| CT                    | 16(38.1)                  | 68(54.8) | 52(48.6) | 0.285 | 0.680(0.34-1.38) | 68(54.8) | 51(47.7) | 0.393 | 0.730(0.36-1.50) |
| TT                    | 9(21.4)                   | 35(28.2) | 51(47.7) | 0.672 | 0.840(0.38-1.88) | 35(28.2) | 35(32.7) | 0.991 | 1.010(0.46-2.19) |
| TT VS. CT+CC          |                           |        |        |           | 0.291 | 0.700(0.36-1.36) | 0.519 | 0.800(0.41-1.57) |
| p<sub>in</sub>        | 0.2                       | 0.217 | 0.778 |           | 0.217 | 0.775 |           |         |           |         |           |
| pri-let-7f-2 rs17276588|                           |        |        |           |        |        |           |         |           |         |           |
| GG                    | 60(69.8)                  | 81(65.3) | 64(59.8) | 1   | 81(65.3) | 70(65.4) | 1   |         |         |           |
| GA                    | 14(16.3)                  | 23(18.5) | 16(15.0) | 0.853 | 0.930(0.43-2.03) | 23(18.5) | 18(16.8) | 0.974 | 0.999(0.46-2.12) |
| AA                    | 12(14.0)                  | 20(16.1) | 27(25.2) | 0.067 | 1.380(0.98-1.95) | 20(16.1) | 19(17.8) | 0.846 | 1.040(0.73-1.48) |
| AA Vs. GA+GG          |                           |        |        |           | 0.700 | 1.060(0.36-1.36) | 0.217 | 1.240(0.88-1.75) |
| p<sub>in</sub>        | 0.010                     | 0.000 | 0.000 |           | 0.000 | 0.000 |           |         |           |         |           |

Note: *using Logistic Regression adjusted by sex, age and H. pylori infection status; †means Hardy-Weinberg Equilibrium in population; CON: controls; AG: atrophic gastritis; GC: gastric cancer; NCBI Ref: the reference polymorphism frequencies in Beijing, China in NCBI database.
doi:10.1371/journal.pone.0095249.t001

Polymorphism of rs629367 in let-7a-2 Is Associated with Gastric Cancer

The commercial expression plasmid pCMV-MIR-let-7a-2 rs629367-C was purchased from Origene Company (Origene Biotech Co., Ltd, Shanghai, China). This plasmid was conducted a site-specific mutagenesis at -216 from C to A (pCMV-let-7a-2 rs629367-A) by Sainuo Company (Sainuo Biotech Co., Ltd, Beijing, China) and confirmed by sequencing. And the candidate cell lines were sequenced to genotype the pri-let-7a-2 rs629367 site to explore whether there was any variant of this rs629367 polymorphism site. Then, the cell lines of the wild-type and also the lowest two let-7a expression, SGC-7901 and AGS, were selected for transfection (More details see Supplementary Methods and Supplementary Figure S2). The human gastric carcinoma cell line, AGS was purchased from ATCC, American Type Culture Collection, USA and SGC-7901 was purchased from the Cell Bank of Chinese Academy of Sciences, Shanghai, China. After 72 hours, the total RNA of cells was extracted and Real-time PCR was used to detected let-7a expression after reverse transcription in order to compare the mature let-7a produced by pCMV-let-7a-2 rs629367-A vs. pCMV-let-7a-2 rs629367-C.
Statistics

The studied four miRNA polymorphisms were tested for Hardy–Weinberg equilibrium (HWE) among the controls. The continuous variables were shown as mean±standard deviation (SD) and compared by analysis of variance, while the discrete variables were represented as frequencies and percentages and compared by χ2 test [24]. Multivariate logistic regression with adjustments for age, sex and H. pylori infection was used to test the association between miRNA polymorphisms and disease risks. Because smoking and alcohol consumption had nearly a third missing data were not suitable as adjustment factors, only as stratified factors for analysis of the association between the miRNA polymorphisms and disease risks. Univariate and multivariate survival analyses were carried out by the log-rank test and the Cox proportional hazards model. The survival curves were mapped by using the Kaplan–Meier method. Multivariate survival analysis was carried out by adding SNP to all clinicopathological parameters with P<0.05. In addition, the copies of miRNA were used for value for a normal distribution, and the effect of miRNA polymorphisms on its expression levels were tested by the analysis of variance (ANOVA) test. The correlation of let-7a expression in serum and tissue was shown as correlation coefficient by the correlation analysis. Statistical analysis was performed using SPSS version 16.0 software (SPSS, Chicago, IL, USA) and in the screening stage, p values <0.10 was considered significant while all other analyses was considered p values <0.05 as significant.

Results

Main effect of miRNA polymorphisms on gastric cancer and atrophic gastritis risk

The genotype frequencies of the studied SNP in the screening stage were shown in Table 1 and the electrophoretogram and sequencing figure of these four miRNA polymorphisms genotypes were shown in Supplementary Figure S1. pri-let-7a-1 rs17276588 was excluded from further analysis because it deviated from HWE. Two SNPs were considered promisingly to be associated with disease risks: the variant genotype frequencies of pri-let-7a-1 rs10739971 between atrophic gastritis and control group showed statistical difference (27.1% vs. 13.7%, P=0.018, Table 1), and the variant genotype frequencies of pri-let-7a-2 rs629367 between gastric cancer and control group also showed difference (1.9% vs. 6.5%, P=0.094, Table 1). We considered p value <0.10 as significant and selected this two promising SNP sites into the validated stage.

To confirm the association of pri-let-7a-1 rs10739971 and pri-let-7a-2 rs629367 polymorphisms with gastric cancer and/or atrophic gastritis risks, we re-evaluated these two SNPs in another 1949 cases in the enlarged validated stage. The frequencies of the polymorphisms in all the samples were shown in Supplementary Table S2. Healthy controls were frequency matched to gastric cancer and atrophic gastritis cases by age (<5 years) and sex (1:1). After frequency matching, only 501 gastric cancer and 501 controls for gastric cancer risk analysis and 612 atrophic gastritis and 612 controls for atrophic gastritis risk analysis were finally included. In the enlarged validated stage, the variant genotype frequencies of pri-let-7a-2 rs629367 between gastric cancer and control group were statistically different (6.4% vs. 4.0%, Table 1). When compared with the common AA genotype, the variant CC genotype was associated with a 1.83-fold increased risk of gastric cancer (P=0.048, 95%CI = 1.01–3.32, Table 1), and was also associated with a 1.86-fold increased risk of atrophic gastritis (P=0.032, 95%CI = 1.06–3.28, Table 1). In addition, the variant CC genotype was associated with a 1.93-fold increased risk of atrophic gastritis compared with the (AA+AC) genotypes (P=0.021, 95%CI = 1.11–3.36, Table 1). However, we did not observe statistically significant association between pri-let-7a-1 rs10739971 and disease risks in the validated stage.

Stratified analysis and interaction analysis

To further investigate the potential influence of age, sex and environmental factors like status of H. pylori infection, smoking and alcohol drinking on genetic effect, we performed stratified analyses for pri-let-7a-1 rs10739971 and pri-let-7a-2 rs629367 polymorphisms based on those factors (Table 2). We observed different effects of pri-let-7a-2 rs629367 on disease risk in different subgroups. Statistical association between CC genotype and increased atrophic gastritis risk were found in females (P=0.025, OR[95%CI] = 2.59[1.13–5.92]), H. pylori serology-negative subgroup (P=0.036, OR[95%CI] = 1.97[1.05–3.73]), and in non-drinking subgroup (P=0.023, OR[95%CI] = 2.44[1.13–5.26]). In addition, the CC genotype was found to be associated with increased gastric cancer risk in patients with age ≤50 years old (P=0.026, OR[95%CI] = 6.02[1.24–29.10]), and H. pylori serology-negative subgroup (P=0.036, OR[95%CI] = 2.02[1.05–3.90]). However, when we performed the interaction analysis between rs629367 SNP and H. pylori infection, smoking and alcohol drinking, no statistical interaction effect was found (Pinteraction = 0.786 and 0.382 respectively, see Supplementary Table S3). No significant association was found between pri-let-7a-1 rs10739971 and gastric cancer or atrophic gastritis risks in any stratified analysis.

Correlation between pri-let-7a-2 rs629367 polymorphism and clinicopathologic parameters and length of survival of gastric cancer patients

Because of the observation of statistically significant association between rs629367 and gastric cancer and atrophic gastritis risk in the main effect analyses and stratified analyses, we further investigated whether the risk-associated rs629367 correlates with the clinicopathologic phenotype and prognostic survival of gastric cancer. The results showed that no significant correlation of this SNP was found with clinicopathologic parameters including tumor size, tumor location, Borrmann type, histologic type, Lauren type, TNM stage, growth pattern, depth of invasion, lymphatic metastasis, H. pylori infection status, smoking, drinking, and family history (P>0.05, see Supplementary Table S4), but this SNP was found associated with gastric cancer survival. The CC genotype carriers showed unfavorable survival (CC vs. AA: 22.2 months vs. 32.0 months) and increased HRs for gastric cancer patients in univariate analysis (CC vs. AA: P=0.011, HR[95%CI] = 3.39[1.33–8.63]), CC vs. AA+AC: P=0.005, HR[95%CI] = 3.51[1.43–8.49], Table 3 and Figure 1-A and -B). By adjusting for several clinicopathological parameters which were potential confounding factors correlated with gastric cancer survival (P≤0.001 for tumor size, Borrmann type, TNM stage, depth of invasion and lymphatic metastasis, see Supplementary Table S5), statistically increased HRs were also obtained for CC carriers in the multivariate analysis (CC vs. AA: P=0.004, HR[95%CI] = 4.48[1.60–12.60]; CC vs. AA+AC: P=0.001, HR[95%CI] = 4.69[1.84–11.93], Table 3).

Correlation between rs629367 and mature let-7a expression in serum and gastric tissue

In order to study the possible mechanism of rs629367 polymorphism related to gastric cancer, we further investigated the mature let-7a expression in vivo and vitro. The patients’
| Variable       | Trait     | Genotype | AG vs CON | P   | OR(95%CI)* | GC vs CON | P   | OR(95%CI)* |
|----------------|-----------|----------|-----------|-----|------------|-----------|-----|------------|
| let-7a-2 rs629367 | Age       | ≤50      | AA 119/128 | 1   | 80/85 1    | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 76/76   | 0.872 | 37/54 0.303 | CC 14/4   | 0.065 | 3.22(0.93–11.16) |
|                |           |         | CC 14/4   | 0.065 | 9/2 0.034 | GC vs. CA+AA | 0.067 | 3.15(0.92–10.77) |
|                |           | >50      | AA 245/232 | 1   | 208/218 1   | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 133/151 | 0.872 | 144/124 0.261 | CC 21/21 | 0.041 | 1.97(1.03–3.77) |
|                |           |         | CC 14/4   | 0.041 | 9/2 0.034 | GC vs. CA+AA | 0.067 | 3.15(0.92–10.77) |
|                | Sex       | Male     | AA 183/192 | 1   | 195/193 1   | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 130/126 | 0.872 | 116/125 0.411 | CC 21/21 | 0.041 | 1.97(1.03–3.77) |
|                |           |         | CC 20/15  | 0.041 | 22/15 0.226 | GC vs. CA+AA | 0.067 | 1.56(0.81–3.00) |
|                |           | Female   | AA 181/168 | 1   | 93/110 1    | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 79/101  | 0.872 | 65/53 0.067 | CC 19/10 | 0.051 | 2.32(0.99–5.39) |
|                |           |         | CC 14/4   | 0.051 | 9/2 0.034 | GC vs. CA+AA | 0.067 | 1.56(0.81–3.00) |
|                | H. pylori  | Negative | AA 135/288 | 1   | 164/243 1   | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 82/173  | 0.872 | 104/141 0.618 | CC 20/21 | 0.041 | 1.97(1.03–3.77) |
|                |           |         | CC 20/21  | 0.041 | 23/16 0.028 | GC vs. CA+AA | 0.067 | 1.56(0.81–3.00) |
|                |           | Positive | AA 229/72  | 1   | 124/60 1    | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 127/54  | 0.872 | 77/37 0.954 | CC 19/4 | 0.051 | 2.32(0.99–5.39) |
|                |           |         | CC 14/4   | 0.051 | 9/2 0.034 | GC vs. CA+AA | 0.067 | 1.56(0.81–3.00) |
|                | Smoking   | Never Smoker | AA 209/170 | 1   | 81/122 1    | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 114/101 | 0.872 | 53/64 0.163 | CC 21/13 | 0.067 | 2.39(1.09–5.27) |
|                |           |         | CC 21/13  | 0.067 | 9/2 0.034 | GC vs. CA+AA | 0.067 | 2.39(1.09–5.27) |
|                |           | Ever Smoker | AA 82/77 | 1   | 69/75 1    | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 54/57  | 0.872 | 50/54 0.966 | CC 30/15 | 0.067 | 2.39(1.09–5.27) |
|                |           |         | CC 8/6   | 0.067 | 9/2 0.034 | GC vs. CA+AA | 0.067 | 2.39(1.09–5.27) |
|                | Drinking  | Nondrinker | AA 233/192 | 1   | 87/145 1    | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 129/121 | 0.872 | 52/82 0.463 | CC 25/12 | 0.030 | 2.39(1.09–5.27) |
|                |           |         | CC 25/12  | 0.030 | 9/7 0.096 | GC vs. CA+AA | 0.023 | 2.44(1.13–5.26) |
|                |           | Drinker  | AA 58/55  | 1   | 41/52 1    | GG 104/116 | 0.872 | 1.04(0.66–1.63) |
|                |           |         | CA 39/37  | 0.872 | 37/36 0.646 | CC 4/7 | 0.056 | 0.67(0.17–2.66) |
|                |           |         | CC 4/7   | 0.056 | 6/7 0.950 | GC vs. CA+AA | 0.040 | 0.65(0.17–2.54) |
| Variable | Genotype       | AG vs CON | P     | OR(95%CI)* | GC vs CON | P     | OR(95%CI)* |
|----------|----------------|-----------|-------|-----------|-----------|-------|-----------|
|          |                | n = 1224  |       |           | n = 1002  |       |           |
| let-7a-1 rs10739971 |                |           |       |           |           |       |           |
| Age      |                |           |       |           |           |       |           |
| ≤50      | GG             | 50/66     | 1     |           | 33/48     | 1     |           |
|          | GA             | 120/101   | 0.218 | 1.39(0.82–2.34) | 52/62 | 0.252 | 1.43(0.77–2.66) |
|          | AA             | 39/41     | 0.486 | 1.24(0.68–2.27) | 33/31 | 0.086 | 1.84(0.92–3.71) |
|          | AA Vs. GA+GG   | 0.842     | 1.06(0.61–1.83) | 0.160 | 1.53(0.85–2.76) |
| >50      | GG             | 128/137   | 1     |           | 113/127   | 1     |           |
|          | GA             | 193/199   | 0.976 | 1.00(0.71–1.39) | 175/178 | 0.777 | 1.05(0.75–1.48) |
|          | AA             | 82/68     | 0.621 | 1.12(0.72–1.74) | 55/55 | 0.612 | 1.13(0.71–1.79) |
|          | AA Vs. GA+GG   | 0.680     | 1.09(0.74–1.60) | 0.672 | 1.10(0.72–1.67) |
| Sex      |                |           |       |           |           |       |           |
| Male     | GG             | 110/117   | 1     |           | 98/117    | 1     |           |
|          | GA             | 162/164   | 0.632 | 0.91(0.63–1.33) | 152/163 | 0.581 | 1.11(0.77–1.59) |
|          | AA             | 61/52     | 0.733 | 1.09(0.66–1.79) | 59/53 | 0.127 | 1.45(0.89–2.35) |
|          | AA Vs. GA+GG   | 0.659     | 1.11(0.71–1.74) | 0.149 | 1.37(0.89–2.10) |
| Female   | GG             | 68/86     | 1     |           | 48/58     | 1     |           |
|          | GA             | 151/136   | 0.117 | 1.41(0.92–2.17) | 75/77 | 0.537 | 1.18(0.70–1.99) |
|          | AA             | 60/57     | 0.373 | 1.26(0.76–2.11) | 29/33 | 0.741 | 1.12(0.58–2.16) |
|          | AA Vs. GA+GG   | 0.912     | 1.03(0.66–1.60) | 0.923 | 1.03(0.57–1.85) |
| H.pylori | Negative       | GG        | 80/160| 1         |           | 80/137 | 1         |
|          | GA             | 112/241   | 0.686 | 0.93(0.66–1.32) | 116/195 | 0.902 | 1.02(0.71–1.47) |
|          | AA             | 45/81     | 0.608 | 1.13(0.71–1.79) | 55/68 | 0.123 | 1.43(0.91–2.26) |
|          | AA Vs. GA+GG   | 0.435     | 1.18(0.78–1.76) | 0.095 | 1.41(0.94–2.10) |
|          | Positive       | GG        | 98/43 | 1         | 66/38     | 1     |           |
|          | GA             | 201/59    | 0.105 | 1.47(0.92–2.34) | 11/45 | 0.207 | 1.41(0.83–2.39) |
|          | AA             | 76/28     | 0.484 | 1.23(0.69–2.16) | 33/18 | 0.791 | 1.10(0.54–2.25) |
|          | AA Vs. GA+GG   | 0.810     | 0.94(0.58–1.54) | 0.742 | 0.90(0.47–1.70) |
| Smoking  | Never Smoker   | GG        | 100/94| 1         | 42/68     | 1     |           |
|          | GA             | 176/149   | 0.638 | 1.10(0.74–1.64) | 69/101 | 0.678 | 1.12(0.66–1.92) |
|          | AA             | 68/41     | 0.300 | 1.33(0.78–2.27) | 23/25 | 0.423 | 1.36(0.64–2.91) |
|          | AA Vs. GA+GG   | 0.429     | 1.21(0.75–1.94) | 0.463 | 1.29(0.65–2.56) |
|          | Ever Smoker    | GG        | 42/57 | 1         | 35/56     | 1     |           |
|          | GA             | 79/63     | 0.524 | 1.21(0.67–2.18) | 59/60 | 0.182 | 1.51(0.83–2.75) |
|          | AA             | 23/20     | 0.575 | 1.25(0.57–2.73) | 21/19 | 0.200 | 1.70(0.75–3.84) |
|          | AA Vs. GA+GG   | 0.994     | 1.00(0.48–2.09) | 0.372 | 1.40(0.67–2.93) |
| Drinking | Nondrinker     | GG        | 115/114| 47/89     | 1         |       |           |
|          | GA             | 198/167   | 0.619 | 1.10(0.75–1.61) | 70/118 | 0.652 | 1.12(0.68–1.85) |
|          | AA             | 74/44     | 0.274 | 1.33(0.80–2.23) | 20/27 | 0.651 | 1.19(0.56–2.54) |
|          | AA Vs. GA+GG   | 0.455     | 1.19(0.75–1.89) | 0.651 | 1.17(0.59–2.32) |
|          | Drinker        | GG        | 27/37 | 1         | 17/35     | 1     |           |
|          | GA             | 57/45     | 0.393 | 1.34(0.68–2.65) | 42/43 | 0.087 | 1.97(0.91–4.30) |
|          | AA             | 17/17     | 0.625 | 1.24(0.52–2.96) | 14/17 | 0.245 | 1.84(0.66–5.12) |
|          | AA Vs. GA+GG   | 0.907     | 0.95(0.43–2.10) | 0.843 | 1.09(0.46–2.57) |

Note: * using Logistic Regression adjusted by the other two factors of sex, age and H.pylori infection status; CON: controls; AG: atrophic gastritis; GC: gastric cancer. doi:10.1371/journal.pone.0095249.t002
characteristics selected for the study of expression in serum and tissue were shown in Supplementary Table S6. In serum level, stratified by different diseases, we found that in atrophic gastritis group, the mature let-7a expression of rs629367 AA, CA, CC genotype showed a tendency of gradually increasing, and this difference had a statistical significance (3.30 ± 0.56 Vs. 3.52 ± 0.55 Vs. 3.76 ± 0.34, \( P = 0.043 \), Table 4, Figure 2-A). In tissue level, we analyzed the effect on let-7a SNP genotypes on its mature let-7a expression in gastric cancer tissue, and found rs629367 AA, CA, CC genotype also showed a tendency of gradually increasing, although this difference did not reach statistical significance (Table 4).

The mature let-7a expression of pCMV-MIR-pri-let-7a-2 rs629367-A and -C

First, the candidate cell lines were sequenced to genotype the pri-let-7a-2 rs629367 site and found that these candidate cell lines were all rs629367 wild-type (see Supplementary Figure S3). In the vitro level, SGC-7901 and AGS cell lines were transinfected into two plasmids, pCMV-MIR-pri-let-7a-2 rs629367-A and pCMV-MIR-pri-let-7a-2 rs629367-C. After 72 hours, mature let-7a expression had statistical significance in SGC-7901 cell line (\( P<0.001 \), Figure 2-B). The variant C allele expressed a higher let-7a when compared with the ancient A allele. The AGS cell line got no statistical significance and only showed tendency in accordance with SGC-7901 (see Supplementary Figure S4).

Discussion

Based on various studies concerning mature miRNAs functions [30], it has been well accepted that miRNA play an important role in the development of cancer as an “oncogene” or “tumor suppressor gene” [31]. However, the relationship between miRNA variants and cancer risk as well as prognosis still needs to be clarified [32]. In the present study, we reported, for the first time, the distribution frequencies of four miRNA tagSNPs (pri-let-7a-1 rs10739971, pri-let-7a-2 rs629367 and rs1143770, pri-let-7f-2 rs17276588) in Northern Chinese. We further validated the promising polymorphism sites in independent and expanded samples and found the variant CC genotype of pri-let-7a-2 rs629367 increased the risks of gastric cancer and atrophic gastritis to 1.83 and 1.86 fold, as well as associated with a poor survival of gastric cancer patients. We further explored the effect of pri-let-7a-2 rs629367 on its expression and the possible mechanisms, and indicated that the mechanism might due to the alternation of the mature let-7a expression, which may eventually alter the susceptibility and prognosis for gastric cancer. To our knowledge,
this is the first report about the relationship of rs629367 SNP with susceptibility and prognosis of gastric cancer.

As we know, genetic variations, which arise in miRNA genes including their pri- and pre-miRNA regions, would have opportunity to affect several biologic pathways and influence disease incidence [33]. Thus, pri- and pre-miRNA polymorphisms may be used as genetic markers for predicting cancer risk [32,34], which have more advantage and strengths than coding gene polymorphisms at the predicting potential because miRNAs frequently located in cancer-associated genomic regions [35] and could regulate almost all the encoding genes [36]. Recently, various studies focused on the pre-miRNA polymorphisms located on the stem-loop, such as pre-mir-196a2 rs11614913 [37], pre-mir-146a rs2910164 [38], pre-mir-499 rs3746444 [39,40], pre-mir-149 rs2292832 [41], pre-mir-27a rs895819 [42]. Because of the complexity of RNA space structure, increasing attention had been paid to SNP on pri-miRNA. The representative pri-miRNA SNPs were pri-miR-185 rs2008591 associated with breast cancer [11], pri-miR-34b/c rs4938723 associated with hepatocellular cancer [12], pri-miR-30c rs928508 [22] and pri-miR-938 rs2505901 [43] associated with gastric cancer. let-7 families were most previous identified miRNAs [4] and play a crucial role in maintaining the normal physiologic function of human. By using NCBI bioinformatics databases, we found 4 SNPs in the primary precursor area of let-7 family (pri-let-7a-1 rs10739971, pri-let-7a-2 rs629367 and rs1143770, pri-let-7f-2 rs17276588) had Minor Allele Frequency (MAF)>5% in Chinese population, which were all tagSNPs but their potential predicting roles were unclear. In the present study, by screening and validating two stages study we first found that, among 4 tagSNPs, pri-let-7a-2 rs629367 polymorphism was associated with susceptibility of gastric cancer (the variant CC genotype of pri-let-7a-2 rs629367 increased the risks of gastric cancer and atrophic gastritis to 1.83 and 1.86 fold). This pri-let-7a-2 rs629367 SNP was located in downstream 3′-UTR, which was the nearest SNP with the mature miRNA genes among the four screening SNPs, and it would be a new biomarker in predicting gastric cancer risk.

We further performed univariate and multivariate Cox proportional hazards regression analysis of the follow-up data to explore the associations of pri-let-7a-2 rs629367 SNP with overall survival of gastric cancer patients. Consistently significant results were observed from univariate and multivariate Cox models (Table 3). The pri-let-7a-2 rs629367 variant CC genotype carriers showed increased HR with a P-value of 0.011 (HR = 3.39) and 0.005

### Table 4. The expression of let-7a and the effect of pri-let-7a-2 rs629367 polymorphism to its mature miRNA expression.

| rs629367 Genotype | CON(n) | AG(n) | GC(n) | Cancer Tissue(n) | Noncancer Controls(n) |
|-------------------|-------|------|------|-----------------|---------------------|
| AA    | 54    | 57   | 93   | 62              | 62                  |
| AC    | 38    | 37   | 61   | 27              | 27                  |
| CC    | 8     | 6    | 10   | 5               | 8                   |

P- value: 0.746 and 0.043

Note: *means the variance analysis was used to calculate the difference between the expressions of three genotypes.

doi:10.1371/journal.pone.0095249.t004

**Figure 2. The effect of pri-let-7a rs629367 A/C SNP on the mature let-7a expression in vivo and vitro.**

A. The let-7a expression of different genotype of pri-let-7a-2 rs629367 in atrophic gastritis group in serum samples. B. the cell mature let-7a expression transinfected by different pri-let-7a-2 rs629367 plasmid. *P<0.001.

doi:10.1371/journal.pone.0095249.g002
Polymorphism of rs629367 in let-7a-2 Is Associated with Gastric Cancer

Polymorphism of rs629367 in let-7a-2 is associated with gastric cancer. Therefore, the removal of these two environmental factors made the ORs higher than analyzing the whole samples. Furthermore, we performed an interaction analysis of rs629367 SNP with environmental factors including H. pylori infection, smoking and drinking but we did not find significant interaction effect with environmental factors such as H. pylori infection, smoking and drinking in atrophic gastritis or in gastric cancer (P_interactions > 0.05). This phenomenon may be because both pri-let-7a-2 polymorphism and environmental factors contributed to the risk of gastric cancer but the contribution of environmental factors like H. pylori infection and drinking was much stronger than the weak effect of gene polymorphisms, and the two factors could not reach an interaction effect of addition or multiplication. And only when removing the environmental factors, the association of polymorphisms with disease risks could demonstrate apparently.

Several limitations still remain in our study: first, in this study, there was a statistical significance of the effect of pri-let-7a-2 rs629367 polymorphism to mature let-7a expression in serum, and we only see the same tendency in tissue but this did not reach statistical difference. The significance of the effect of this rs629367 polymorphism to only serum let-7a expression might be limited and should be further studied and datamined in a larger sample size. Second, the specific functions of this rs629367 required further clarification, for example, whether the variant C has a different biological function from the ancient A; third, the relation of pri-let-7a-2 rs629367 SNP with gastric cancer prognosis observed in this study was exploratory, which requires future larger-scale study to confirm. In the future, larger and multi-centers samples are needed to confirm our findings, and the possible mechanisms need to be clarified by further molecular experiments.

Conclusions

In summary, our study revealed that pri-let-7a-2 rs629367 CC genotype could increase the risks of gastric cancer and atrophic gastritis and was also associated with poor survival of gastric cancer, which possibly by affecting the mature let-7a expression. The pri-let-7a-2 rs629367 CC genotype might have application prospect to serve as a predicting biomarker for high-risk and poor prognosis of gastric cancer.

Supporting Information

Figure S1 The electrophoretogram and sequencing figure of four miRNA polymorphisms genotypes. The electrophoretogram and sequencing figure of four miRNA polymorphisms genotypes. A. pri-let-7f-2 rs17276588 SNP: M, 100 bp DNA Marker (TAKARA); Lane 1,2,6,7: GG homozygote; Lane 3,4,5: GA heterozygote; Lane 6: GA heterozygote; Lane 5: AA homozygote. B. pri-let-7a-2 rs629367 SNP: M, 100 bp DNA Marker (TAKARA); Lane 1,2,6,7: CC homozygote; Lane 3,4,5: CT heterozygote; Lane 5: TT homozygote. C. pri-let-7a-2 rs629367 SNP: M, 100 bp DNA Marker (TAKARA); Lane 6: CC homozygote; Lane 5: CT heterozygote; Lane 4: TT homozygote. D. pri-let-7a-2 rs629367 SNP: M, 100 bp DNA Marker (TAKARA); Lane 6: CC homozygote; Lane 5: CT heterozygote; Lane 4: TT homozygote. E. pri-let-7a-2 rs629367 SNP: M, 100 bp DNA Marker (TAKARA); Lane 6: CC homozygote; Lane 5: CT heterozygote; Lane 4: TT homozygote. (TIF)

Figure S2 The selection of cell lines for pCMV-MIR-let-7a-A torf C plasmid transfection. The selection of cell lines for
transinfected by different pri-let-7a-2 rs629367 plasmid. This figure showed endogenous let-7a expressed by different cell lines (GES-1, AGS, SGC-7901, BGC-823, BGC-803, MKN-45, N87). The least cell line expressed endogenous let-7a, SGC-7901 and AGS, were selected for transfection because it could reduce the effect that endogenous let-7a participated in the transcription experiments on the other hand could warrant let-7a upstream or downstream pathway molecules existed.

Figure S3 The pri-let-7a-2 rs629367 genotype of the candidate cell lines. The pri-let-7a-2 rs629367 genotype of the candidate cell lines was sequenced. The human gastric cell lines, GES-1, AGS, SGC-7901, BGC-803 and NCI-N87 was all rs629367 A allele, which suggested no variant genotype among them for interference.

Figure S4 The mature let-7a expression in AGS cell line transfected by different pri-let-7a-2 rs629367 plasmid.

Table S1 The demographic geography characteristics.

Table S2 The frequencies of pri-let-7a-2 rs629367 and pri-let-7a-1 rs10739971 polymorphism in the MassArray assay.

References
1. Ryan BM, Robles AI, Harris CC (2010) Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 10: 389–402.
2. Duan R, Pak C, Jin P (2007) Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet 16: 1124–1131.
3. Sarver AL, Li L, Subramanian S (2010) MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumour cell migration. Cancer Res 70: 9750–9760.
4. Pasquinielli AE, Reinhart BJ, Slack F, Martinou MQ, Kuroda MI, et al. (2000) Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 406: 186–89.
5. Ambros V, Lee RC, Lau WC, Garewal H, Reizenstein J, et al. (2003) MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr Biol 13: 897–904.
6. Schulte A (2010) Great expectations of small RNAs. Nat Rev Mol Cell Biol 11: 676.
7. Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597–610.
8. Kumar MS, Liu J, Mercer KL, Golah TR, jacobs T (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673–677.
9. Brookes AJ (1999) The essence of SNPs. Gene 234: 177–186.
10. Shastry BS (2009) SNPs impact on gene function and phenotype. Methods Mol Biol 537: 3–22.
11. Benem JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR, et al. (2013) Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control 24: 109–119.
12. Xu Y, Liu L, Liu J, Zhang Y, Zhu J, et al. (2011) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer 128: 412–417.
13. Hansen T, Olsen L, Lindow M, Jakobsen KD, Ullum H, et al. (2007) Brain causes control 24: 109–119.
14. Bensen JT, Tse CK, Nyante SJ, Barnholtz-Sloan JS, Cole SR, et al. (2013) Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study. Cancer Causes Control 24: 109–119.
15. Zhou J, Peng R, Li T, Luo X, Peng H, et al. (2013) A potentially functional polymorphism in the regulatory region of let-7a-2 is associated with an increased risk for diabetic nephropathy. Gene 527: 456–461.
16. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827–841.
17. Long N, Moore MA, Chen W, Gao CM, Lai MS, et al. (2010) Cancer epidemiology and control in north-East Asia - past, present and future. Asian Pac J Cancer Prev 11 Suppl 2: 107–148.
18. Leung WK, Wu MS, Kukagawa Y, Kim JJ, Yeoh KG, et al. (2008) Screening for gastric cancer in Asian current evidence and practice. Lancet Oncol 9: 279–287.
19. Wang F, Sun GP, Zou YF, Fan LL, Song B (2013) Quantitative assessment of the association between miR-196a2 rs1614913 polymorphism and gastrointestinal cancer risk. Mol Biol Rep 40: 109–116.
20. Wu XJ, Mi YY, Yang H, Hu AK, Li C, et al. (2013) Association of the hsa-mir-499 (rs3746444) Polymorphisms with Gastric Cancer Risk in the Chinese Population. Onkologie 36: 573–576.
21. Zhou F, Zhu H, Luo D, Wang M, Dong X, et al. (2012) A functional polymorphism in pre-miR-146a is associated with susceptibility to gastric cancer in a Chinese population. DNA Cell Biol 31: 1290–1295.
22. Mu YP, Xu XL (2012) Polymorphism in pre-miR-30c: contributes to gastric cancer risk in a Chinese population. Med Oncol 29: 1723–1732.
23. Lauren P (1965) The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-called Intestinal-Type Carcinoma. an Attempt at a Histo-clinical Classification. Acta Pathol Microbiol Scand 64: 32–49.
24. Xu Q, Chen MY, He CY, Sun LP, Yuan Y (2013) Promoter polymorphisms in trefoil factor 2 and trefoil factor 3 genes and susceptibility to gastric cancer and atrophic gastritis among Chinese population. Gene 529: 104–112.
25. Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20: 1161–1161.
26. Sohli M, Meining A (2001) The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. Can J Gastroenterol 15: 591–598.
27. Xu Q, Yuan Y, Sun LP, Gong YH, Xu X, et al. (2009) Risk of gastric cancer is associated with the MUC1 568 A/G polymorphism. Int J Oncol 35: 1313–1320.
28. Gong YH, Sun LP, Jin SG, Yuan Y (2010) Comparative study of serology and histology based detection of Helicobacter pylori infections: a large population-based study of 7,241 subjects from China. Eur J Clin Microbiol Infect Dis 29: 907–911.
29. Liu R, Zhang C, Hu Z, Li G, Wang C, et al. (2011) A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 47: 784–791.
30. Chen FS, Su JL, Hung MC (2012) Dysregulation of microRNAs in cancer. J Biomed Sci 19: 90.
31. Fabбри M, Calore F, Paone A, Galli R, Calin GA (2013) Epigenetic regulation of miRNAs in cancer. Adv Exp Med Biol 754: 137–148.
32. Salzman DW, Weidhaas JB (2013) SNPs in cancer: the microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther 137: 55–63.
33. Fabбри M, Valeri N, Calin GA (2009) MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. Carcinogenesis 30: 912–917.
34. Srivastava K, Srivastava A (2012) Comprehensive review of genetic association studies and meta-analyses on microRNA polymorphisms and cancer risk. PLoS One 7: e50966.
35. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999–3004.
36. Mishra PJ, Bertino JR (2009) MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10: 399–416.
37. Wang P, Xie S, Cui A, Zhang Y, Jiang B (2013) miR-196a2 polymorphisms and susceptibility to cancer: A meta-analysis involving 24,697 subjects. Exp Ther Med 3: 324–330.

38. Wang J, Bi J, Liu X, Li K, Di J, et al. (2013) Has-miR-146a polymorphism (rs2910164) and cancer risk: a meta-analysis of 19 case-control studies. Mol Biol Rep 39: 4571–4579.

39. Wang N, Tian ZQ, Li Y, Zhou RM, Wang GY (2013) An A/G polymorphism rs3746444 in miR-499 is associated with increased cancer risk: a meta-analysis. Genet Mol Res 12: 3955–3964.

40. Zhang YG, Shi JX, Song GH, Wang P, Dai LP, et al. (2013) Association of mir-499 and mir-149 polymorphisms with cancer risk in the Chinese population: evidence from published studies. Asian Pac J Cancer Prev 14: 2337–2342.

41. Xu L, Zhou X, Qiu MT, Yin R, Wu YQ, et al. (2013) Lack of Association between Hsa-miR-149 rs2292032 Polymorphism and Cancer Risk: A Meta-Analysis of 12 Studies. PLoS One 8: e73762.

42. Xu Q, He CY, Liu JW, Yuan Y (2015) Pre-miR-27a rs895819A/G polymorphisms in cancer: a meta-analysis. PLoS One 8: e65208.

43. Arisawa T, Takara T, Shiroeda H, Matsue Y, Minato T, et al. (2012) Genetic polymorphisms of IL17A and pri-miRNA-938, targeting IL17A 3’-UTR, influence susceptibility to gastric cancer. Hum Immunol 73: 747–752.

44. Zhu YM, Zheng ZX, Liu ZM (2010) Relationship between let-7a and gastric mucosa cancerization and its significance. World J Gastroenterol 16: 3325–3329.

45. Wang WN, Chen Y, Zhang YD, Hu TH (2013) The regulatory mechanism of CCR7 gene expression and its involvement in the metastasis and progression of gastric cancer. Tumour Biol 34: 1865–1871.

46. Lao-Sirieix P, Caldas C, Fitzgerald RC (2010) Genetic predisposition to gastroesophageal cancer. Curr Opin Genet Dev 20: 210–217.

47. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D (2004) Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 159: 252–258.

48. Tramacere I, Pelacchi C, Bagnardi V, Rota M, Scotti L, et al. (2012) A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk. Ann Oncol 23: 287–297.

49. Tramacere I, Negri E, Pelacchi C, Bagnardi V, Rota M, et al. (2012) A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol 23: 28–36.